Login / Signup
Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
Motohiko Adomi
Avik Ray
Published in:
Alimentary pharmacology & therapeutics (2022)
Keyphrases
</>
risk assessment
patients with inflammatory bowel disease